A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

NCT03941873 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular
Gastric/Gastroesophageal Junction Cancer

Interventions

DRUG: Sitravatinib
DRUG: Tislelizumab

Sponsor

BeiGene